LCTX (Lineage Cell Therapeutics) Valuation Rank


LCTX Lineage Cell Therapeutics Inc LCTX
78 GF Score
Price $1.35
GF Value $1.33
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lineage Cell Therapeutics Valuation Rank Related Terms

LCTX
78GF Score
Lineage Cell Therapeutics Inc LCTX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be overvalued. The current stock price of $1.35 is trading 1.5% above its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

  • Valuation Rank:
  • GF Value™: $1.33 vs. price of $1.35 (1.5% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for LCTX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35
Price
$1.33
GF Value